Repressing the immune resistance program

To identify drugs that could potentially be selectively lethal to immune resistant cancer cells we:

1. Computed the overall expression of the immune resistance program across various human cancer cell lines, spanning XX cancer types.

and 2. Used a mixed-effects model that controls for the different cancer types, to identify drugs that are more toxic to immune resistant cancer cell lines. We used the IC50 values of 131 drugs across 639 human cancer cell lines as reported in (Garnett et al., 2012).

find.sensitizing.drugs()

Among the topmost scoring drugs was a CDK4/6-inhibitor (palbociclib, ranked 3rd, P = 1.01*10-4, mixed-effects).